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Introduction
Despite significant advances in cancer therapeutics, including the introduction of immune checkpoint inhibitors (1) (2) (3) (4) (5) (6) , it remains extremely difficult to treat advanced cancers affecting multiple organs and involving distant metastases. Ralph Steinman, the Nobel Prize-winning scientist who discovered dendritic cells (DCs) in 1973 (7), experimentally immunized himself with DC vaccination therapy against his pancreatic cancer and survived for 4.5 years. The manufacturing technology used in the production of antigen-presenting cell (APC)-based immunotherapies involving active DCs, the immune system's most potent APCs, is currently under development as a means of therapeutic vaccination against cancer (8) . DCbased immunotherapy not only appears to be associated with few adverse reactions but also has limited clinical effectiveness when assessed using conventional evaluation methods such as response evaluation criteria in solid tumors (9, 10) . Due to a slow clinical response, a low response rate, and few differences in patient median survival time (MST), long-term cancer immunity results in a delayed separation of treated and untreated patient survival curves, with an eventual treatment advantage in prolonged overall survival (OS) (11, 12 ).
An ex vivo technique is being developed for DC-based cancer vaccination to promote strong induction of T cells against tumor antigens. Oil adjuvants for peptide vaccines act by locally accelerating the activation of lymphocytes (13) . However, DCs have the potential antigen bioactivity and may be used as a suitable adjuvant (14) (15) (16) . Human leukocyte antigen (HLA) molecules harbor cancer antigen peptides that promote DCs binding with receptors on CD8 + killer and CD4 + helper T cells, leading to an immune response against cancers ( Figure 1 ). In contrast, immune suppressor cells, such as regulatory T cells, tolerogenic DCs, and myeloid-derived suppressor cells, suppress autoreactive and cancer-derived mechanisms (17) (18) (19) (20) (21) . Immune suppressive factors are also stimulated by the presence of cancer cells. These factors are shown in Figure  1 and include transforming growth factor-β, interleukin (IL)-10, vascular endothelial growth factor, prostaglandin E2 (PGE2), and programmed death-ligand 1 (PD-L1) (22) . The efficacy of DC vaccination can likely be attributed to the inhibition of these immune suppressors.
DCs are generated from peripheral monocytes following exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4. DCs expressing tumor-specific antigens have been used in active cancer immunotherapies (23, 24) . The most common approach to DC vaccination is the preparation of autologous, mature, monocyte-derived DCs ex vivo with consequent, homogeneous, and functional DC generation. Cancer vaccination therapies are principally attributed to the presence of tumor-associated antigens using peptide, protein, tumor lysate, and RNA (25) (26) (27) (28) (29) . Sipuleucel-T (Provenge ® ) is a US Food and Drug Administration-approved autologous DC-based immunotherapy for men with metastatic hormonerefractory prostate cancer, which provides a new treatment option for patients with this type (52, 53) . This article focuses on a pilot study evaluating autologous DC vaccination targeting WT1 in pediatric patients with neuroblastoma or WT.
Manufacture of a DC vaccine
Mature DCs (mDCs) were generated under Good Gene, Cell and Tissue Manufacturing
Practice, conditions according to the "The Act on the Safety of Regenerative Medicine" introduced in Japan on November 25, 2014 (54) . Mononuclear cell-rich fractions (165 ml)
were isolated from 4,000 ml of the patient's blood through apheresis using a COM.TEC 
DC vaccine release criteria
The antigenic profiles of mDCs were determined using flow cytometry. mDCs were defined March to July 2011. DC vaccine-related toxicities were tolerable and included grade 2 skin reactions and pain at the injection sites along with grade 1 low-grade fever within 48 h of treatment. There were no ≥grade 3 adverse effects due to DC vaccination based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 (http://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf). The tumor markers (neuronspecific enolase, urinary vanillylmandelic acid, and homovanillic acid) were normalized in August 2011, and the magnetic resonance imaging indicated the lesion significantly reduced.
However, the increase of the recurrent tumor with multiple metastasis of bone marrow was detected by MRI and metaiodobenzylguanidine scintigraphy in November 2011. Temozolomide was added, and the DC vaccination was also continued after one course for an additional 15 sessions until October 2012. The patient died due to disease progression in August 2013. Progression-free survival and OS from diagnosis were 5 months after DC vaccination and 4 years and 8 months, respectively. 
Immune monitoring with tetramer analysis
Freshly isolated peripheral blood mononuclear cells were stained with phycoerythrin (PE)-conjugated human immunodeficiency virus/HLA-A*24:02 tetramer as a negative control or with PE-conjugated WT1-modified peptide/HLA-A*24:02 tetramer (MBL; Medical & Biological Laboratories Co., Ltd., Nagoya, Japan). Other stains included allophycocyanin-conjugated anti-CD3 mAb and fluorescein isothiocyanate-conjugated anti-CD8 mAb prior to the analysis by flow cytometry (BD FACSCalibur™ and BD FACSCanto™ II) in Figure 2A . The presence of WT1 antigen-specific CTLs (WT1-CTLs) was defined according to the following criteria: (i) greater than 0.02% WT1-positive cells of all CD8+ T cells analyzing 50,000-10,000 lymphocytes with no evidence of false-positive cells and (ii) WT1-positive population clustered and not diffused as described (57) . WT1-CTLs were determined either by WT1-peptide/HLA-A*24:02 tetramer analysis or by interferon (IFN)-γ-producing clones used in enzyme-linked immunosorbent spot (ELISPOT) assays after DC vaccination as a proof-of-concept analysis. Before DC vaccination in both cases, WT1-CTLs were detectable at levels above 0.02% as previously defined (57) . After one course of DC vaccination, the immune monitoring assay demonstrated that WT1-CTLs consisted of 0.05% and 2.05% of the CD8 + T-cell population in cases 1 and 2, respectively ( Figure 2B and C). WT1-specific T cells were markedly increased after one course during additional vaccination, contributing to the antitumor immune responses noted in our cases ( Figure 2B and C).
DC vaccination technology for pediatric patients
Our preliminary study on pediatric patients has several limitations, such as the small sample size and a heterogeneous group of patients. However, DC vaccination targeting WT1 during a standard therapy course may be both feasible and well tolerated for treating advanced neuroblastoma and WT. The findings also indicated that DC vaccination targeting WT1 generated immunogenicity. WT1-specific CTLs were detected at several levels at the time of initial vaccination, whereas they were distinctly increased after one course of additional vaccination and contributed to induction of the antitumor immune response in our cases. Spontaneous WT1-specific T-cell responses have been reported in acute myeloid leukemia patients (58) . Therefore, one possible explanation for the immune response is that the WT1-specific T cells might have been spontaneously induced in these patients. WT1-specific T-cell responses were interestingly maximal at the last session of the course under their disease progression. It is possible that the response of WT1-specific CTLs might be merely boosted by tumor cell growth, although they were no longer able to control disease progression as described with a case of allogeneic DC vaccination targeting WT1 (53) .
Case 1 with stage IV neuroblastoma, who relapsed 6 months, had the highest risk of death based on the time to first relapse (59). Our patient survived for 38 months after relapse under disease control with DC vaccination and low-dose etoposide, suggesting a survival benefit together with the maintenance of quality of life. WT1-DC vaccination would be helpful when selecting an optimal therapy for poor survival after neuroblastoma relapse. The WT in case 2 was classified as stage III very high risk for subsequent relapse among children with relapsed WTs (60) . Despite the high-dose therapy, MST for very high-risk patients is less than 2 years. It is evident that an effect of the combined modality therapy including DC vaccination achieved the more than 8-year survival after the recurrence in this case, although the contribution of the WT1-DC vaccine to the patient's prolonged survival was unclear.
As the number of WT1-CTLs was positively related to the WT1-specific IFN-γ production according to ELISPOT assays (57), the efficacy of DC vaccination would be presumed to be dependent on the number of WT-CTLs. However, the WT1-CTL response to neuroblastoma cells might be limited due to a lack of and downregulation of HLA-class I antigens in neuroblastoma and other renal cell cancers (61) (62) (63) . Despite an increase in HLA-class I expression on neuroblastoma cells following exposure to IFN-γ (61), there is a concern regarding the attenuation of WT1 antigen in tumor cells during the course of WT1-DC vaccination.
A breakthrough in DC-based vaccine technology is required to achieve further improvement in its cancer treatment efficacy. An allogeneic DC vaccination targeting WT1 may be another potential strategy for patients with relapsed leukemia after HSCT. This strategy may be safe, tolerable, and even feasible for pediatric donors and patients with relapsed leukemia after HSCT as described (52, 53) . A 15-year-old girl with acute lymphoblastic leukemia received allogeneic DC vaccination pulsed with WT1 peptide after her third HSCT. The vaccines were generated from her third HSCT donor, the patient's younger 12-year-old sister, who matched with HLA-A*24:02. The patient received 14 vaccine doses with no occurrence of graft-versus-host disease and no systemic adverse effects apart from a grade 2 local skin reaction at the injection site.
WT1-specific immune responses were detected postvaccination by both WT1 tetramer analysis and ELISPOT assays. The patient experienced 44 months of remission after the third HSCT with DC vaccinations, whereas she had been in remission for less than 14 months between her second and third HSCT. This finding suggests that WT1-specific DC vaccination contributed to the extended period of remission following the patient's third HSCT (53) . One potential approach to overcome the phenomenon of tumor cells escaping immune detection is the generation of IFN-DCs from monocytes using GM-CSF and IFN-α. Mature forms of IFN-DCs would induce CTLs together with their strong adaptive antitumor effects, with natural killer cell activity independent of HLA-class I antigen expression (64) . Another approach is the administration of granulocyte colony-stimulating factor (G-CSF), resulting in the upregulation of monocyte adhesion molecules. An evaluation of the hypothesis that acceleration of acquired cancer immunity using a G-CSF-primed WT1-DC vaccine is related to the type of cancer is ongoing.
The efficacy of DC vaccination may be enhanced by the off-target effects of chemotherapeutic drugs such as gemcitabine (2′,2′-difluorodeoxycytidine, GEM) and a combination of tegafur, gimeracil, and oteracil (48) . It has also been reported that WT1 antigen expression in pancreatic cancer cell lines is increased by GEM treatment (65) . Initial radiotherapy with additional chemotherapeutic drugs acting through their off-target effects may have accelerated the development of acquired cancer immunity and induced antigen-specific CTLs in patients receiving WT1-targeted DC vaccinations (47) . Therefore, DC vaccines in combination with chemotherapy and radiotherapy should promote treatment efficacy against advanced disease. It is necessary to determine the best combinations of the DC vaccine with chemotherapeutic drugs for treating WT and pediatric neoplasms. Immune checkpoint inhibitors are rapidly being developed as chemotherapeutic agents (66) . Further studies are required to evaluate whether effector memory T-cell numbers prior to vaccination and the exhaustion of markers for PD1-positive CTLs after DC vaccination influence the efficacy of DC vaccination. Targeted clinical trials could reveal the effectiveness of DC vaccine in combination with immune checkpoint inhibitors as cancer treatments in the near future. Predictive biomarkers for use with DC vaccination targeting WT1 are highly relevant to the personalized cancer therapy.
Conclusion
Our preliminary study suggests that DC vaccination targeting WT1 administered during the course of standard cancer therapies may be both feasible for and well tolerated by patients with neuroblastoma and WT. The study findings indicate that induction of acquired immunity by targeting WT1 was detected by immune monitoring with tetramer analysis during the course of DC vaccination, confirming the positive results for this proof-of-concept investigation in pediatric patients. The results also suggest that WT1-DC vaccination may prolong the survival of pediatric patients with neoplasms. In contrast, it was not clearly determined whether there was an improvement in patient prognosis following WT1-DC vaccination because both patients died due to disease progression. Therefore, the efficacy and safety of DC vaccination should be determined by phase I/II prospective trials enrolling larger numbers of patients with pediatric neoplasms.
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